TAG:
clinical trials
Proteomic Tests Poised For Clinical Market
CEO SUMMARY: Proteomics-based technology is developing rapidly. The strategic collaboration announced last month between Ciphergen Biosystems and Quest Diagnostics Incorporated is potentially worth $25 million. It is an expensive bet that next-generation proteomics tests soon to enter the…
Urology Revenue Loss Drives AP Lab Condos
CEO SUMMARY: Urologists are motivated to operate anatomic pathology laboratory condominiums as a way to replace lost income after Medicare imposed a major reimbursement cut for a key urology procedure. Capturing revenue from ancillary services is a hot topic within the urology profession….
LabCorp Buys Esoterix For $150 Million in Cash
CEO SUMMARY: Laboratory Corporation of America continues to display an appetite to grow by acquisition. However, its purchase of Esoterix, Inc. creates unique management problems for LabCorp, because Esoterix is itself a product of a lab acquisition strategy. Over the past ten years, Esot…
National Reference Labs Undergoing Changes
CEO SUMMARY: Maybe it’s a coincidence. More likely it is a response to changes in the reference/esoteric marketplace. Specialty, Esoterix, ARUP, and Mayo have each recently reassessed their core strategies and are shifting their business emphasis. Because three of these four companies a…
HPV Vaccine Developers Racing to Marketplace
CEO SUMMARY: At least ten companies are working on an HPV vaccine that can prevent cervical cancer. The leading two companies have Phase III clinical trials under way and expect to earn regulatory approval within the next 24 to 30 months. The speedy arrival of an HPV vaccine in the market…
Medicare Changes Policy On New Med Procedures
CEO SUMMARY: Faced with a literal tidal wave of new medical procedures, new therapeutic drugs, and new diagnostic tests, Medicare is crafting a unique strategy. As a new clinical option reaches the market, Medicare will reimburse—but only if the patient participates in a clinical study …
ChromaVision Targets National AP Market
CEO SUMMARY: Three new business strategies are moving ChromaVision into different segments of the laboratory testing marketplace. The company has built a new laboratory facility and will support local pathology groups with advanced diagnostic technology. It is also expanding its presence …
Leonard Joins AEL’s Board, Cenetron Is Newest Acquisition
There were two big announcements at American Esoteric Laboratories, Inc. (AEL) during the past few weeks. First came news on July 20 that Larry L. Leonard was now on the Board of Directors at AEL. Leonard had been part of the senior executive team at Laboratory Corporation o…
Sysmex Anticipates Major Shifts In Laboratory Testing Market
“Innovating from our core technologies will lead Sysmex into very different areas of laboratory testing.” —John Kershaw CEO SUMMARY: Sysmex America, Inc. surprised many this year when it hired its own sales and service team and begin distribu…
Genomic Health, LabCorp, DIANON Systems
GENETIC ANALYSIS FROM TISSUE BLOCKS UNVEILED IN CHICAGO IT WAS A SPECTACULAR DEBUT for a Northern California company now developing technology to allow genetic analysis of tissue blocks as a way to classify tumors. The company is Genomic Health, Inc., based in Redwood City,…
CURRENT ISSUE
Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.